Related Experiment Video

Updated: May 15, 2026

Multidisciplinary Approach to Obesity Management: A Case Report
05:10

Multidisciplinary Approach to Obesity Management: A Case Report

Published on: May 30, 2025

[Towards evidence-based medicine: large-scale intervention trials with glucagon-like peptide-1 receptor agonists]

Agostino Consoli1, Rosamaria Di Biagio

  • 1Dipartimento di Medicina Interna e Scienze dell'Invecchiamento, Università degli Studi "G. d'Annunzio", Chieti. consoli@unich.it

Giornale Italiano Di Cardiologia (2006)
|December 22, 2012
PubMed

Insights

Glucagon-like peptide-1 (GLP-1) receptor agonists may offer cardiovascular protection beyond glucose control in type 2 diabetes. Ongoing trials will confirm their safety and potential benefits for heart health.

Area of Science:

  • Cardiology
  • Endocrinology
  • Pharmacology

Background:

  • Antihyperglycemic therapy in type 2 diabetes mellitus aims to reduce cardiovascular morbidity and mortality.
  • Diabetes medications must be safe regarding cardiovascular risk.
  • Ideal antidiabetic drugs would offer cardiovascular protection independent of glucose control.

Purpose of the Study:

  • To evaluate the cardiovascular safety and protective effects of glucagon-like peptide-1 (GLP-1) receptor agonists.
  • To explore potential cardiovascular benefits of GLP-1 receptor agonists beyond glycemic control.

Main Methods:

  • Review of experimental studies in animal models.
  • Analysis of preliminary human trial results.
  • Examination of registration trial data for liraglutide.
  • Description of ongoing large, randomized, controlled intervention trials.

Main Results:

  • Experimental and preliminary human data suggest GLP-1 receptor agonists may have cardiovascular protective effects.
  • Liraglutide treatment is associated with improved cardiovascular risk factors.

Conclusions:

  • GLP-1 receptor agonists are potential candidates for cardiovascular protection in type 2 diabetes.
  • Large, randomized trials are necessary to confirm absolute cardiovascular safety and protective effects.

More Related Videos

Randomized Controlled Trial to Study the Acute Effects of Strength Exercise on Insulin Sensitivity in Obese Adults06:13

Randomized Controlled Trial to Study the Acute Effects of Strength Exercise on Insulin Sensitivity in Obese Adults

Published on: December 1, 2023

Related Concept Videos

Glucagon-like Receptor Agonists01:24

Glucagon-like Receptor Agonists

Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...
Hypoglycemia and Glucagon01:15

Hypoglycemia and Glucagon

Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...
Oral Hypoglycemic Agents: Biguanides and Glitazones01:26

Oral Hypoglycemic Agents: Biguanides and Glitazones

Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood glucose levels...
Dipeptidyl Peptidase 4 Inhibitors01:23

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a significant...
Oral Hypoglycemic Agents: Glinides01:06

Oral Hypoglycemic Agents: Glinides

Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively manages...
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors01:19

Oral Hypoglycemic Agents: α-Glucosidase Inhibitors

α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are typically...